In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Anesiva Inc.

Latest From Anesiva Inc.

Novel Pain Therapeutics: When Will Life Get Better On The Island Of Pain?

Nothing has arguably hurt pharmaceutical investors and dealmakers quite so often and with such force as novel pain drug development failures. As a result, a once hot field has gone cold. Despite setbacks, great strides have been made in understanding the complex biology of pain. Scientists have discovered numerous new pain pathway targets with the potential for designing effective agents with fewer off-target effects. Improvements that make preclinical studies more predictive of clinical success are also opening up new opportunities. At the same time, drug developers now understand better how to design drug trials that can segment patient populations to demonstrate therapeutic efficacy more precisely, potentially reducing placebo effects and paving the way for an era of personalized pain medicine.

Wyeth and Mochida end analgesic tie-up

Wyeth (Pfizer) and Mochida Pharmaceutical have ended a licensing deal for a novel class of pain treatments discovered by the mid-sized Japanese firm.

Orthopedics Neurology

Acceleron makes appointments

Acceleron Pharma, a privately held US biopharmaceutical company focused on the discovery, development, manufacture and commercialisation of biotherapeutics that modulate the growth of red blood cells, bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases, has named Melissa Morandi vice-president of quality and Dr Kenneth Attie vice-president of medical research. Ms Morandi joins from Anesiva, where she was vice-president of quality, while Dr Attie was previously vice-president of clinical development and medical affairs at Altus Pharmaceuticals.

Cancer Companies

Anesiva files for bankruptcy after Arcion merger falls through

Anesiva is to file for bankruptcy protection after its proposed merger with Arcion Therapeutics, which appeared to be the struggling pharmaceutical company's saviour in August, was terminated.

Neurology Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Corgentech Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Anesiva Inc.
  • Senior Management
  • Michael L Kranda, CEO & Pres.
    William Houghton, MD, SVP, CMO
    John H Tran, VP, Fin., Chief Accounting Officer
    John Donovan, MD, Exec. Dir., Bus. Dev.
  • Contact Info
  • Anesiva Inc.
    Phone: (650) 624-9600
    400 Oyster Point Blvd.
    Ste. 502
    S. San Francisco, CA 94080